BIAF - bioAffinity Technologies, Inc. Stock Price and Quote

BIAF [NASD]

Healthcare | Diagnostics & Research | USA

Index	-	P/E	-	EPS (ttm)	-	Insider Own	12.70%	Shs Outstand	8.37M	Perf Week	-10.73%
Market Cap	20.85M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.22M	Perf Month	45.62%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.80%	Short Float / Ratio	0.73% / 0.03	Perf Quarter	-11.41%
Sales	0.00M	P/S	8487.38	EPS this Y	13.00%	Inst Trans	-	Short Interest	0.05M	Perf Half Y	-
Book/sh	1.51	P/B	1.54	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-
Cash/sh	1.51	P/C	1.54	EPS next 5Y	-	ROE	-	52W Range	1.31 - 15.55	Perf YTD	45.62%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-85.02%	Beta	-
Dividend %	-	Quick Ratio	9.60	Sales past 5Y	-	Gross Margin	-	52W Low	77.86%	ATR	0.36
Employees	11	Current Ratio	9.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	52.12	Volatility	8.76% 18.92%
Optionable	No	Debt/Eq	0.06	EPS Q/Q	-208.30%	Profit Margin	-	Rel Volume	0.05	Prev Close	2.40
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 14 BMO	Payout	-	Avg Volume	1.31M	Price	2.33
Recom	-	SMA20	7.47%	SMA50	8.16%	SMA200	-15.41%	Volume	70,059	Change	-2.92%

Jan-24-23 08:00AM	bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research Business Wire +75.47%
Jan-04-23 08:00AM	bioAffinity Technologies Announces Notice to Award U.S. Patent Protecting Novel Compounds for Specific Delivery of Cancer Treatments Business Wire +5.77%
Dec-19-22 11:33AM	Argus Research Initiates Equity Research Report Coverage on bioAffinity Technologies, Inc. (NasdaqCM: BIAF) PR Newswire
Dec-15-22 08:30AM	bioAffinity Technologies Expands Diagnostic Division with Promotions and New Hires to Strengthen Clinical Bench Business Wire
Dec-01-22 08:00AM	bioAffinity Technologies Presents Proprietary Cancer Therapeutic Research at Joint ASCB-EMBO Meeting Business Wire
07:30AM	Loading…
Nov-14-22 07:30AM	bioAffinity Technologies Reports Third Quarter 2022 Financial Results and Provides Business Update Business Wire
Nov-10-22 08:15AM	bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Companys Scientific and Medical Advisory Board Business Wire +7.34%
Nov-08-22 08:00AM	bioAffinity Technologies to Report Third Quarter 2022 Financial Results Business Wire
Oct-25-22 09:15AM	bioAffinity Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia Business Wire
Oct-12-22 08:15AM	bioAffinity Technologies Presents Results from Flow Cytometry Analysis of the Lung at CHEST Conference Business Wire
Sep-28-22 08:15AM	bioAffinity Technologies Receives Additional $7.7M from Exercise of Warrants, Total Capital from Public Offering Increases to Approximately $15.6M Business Wire +37.74%
Sep-14-22 08:15AM	bioAffinity Technologies Publishes Peer-Reviewed Results of High-Throughput Flow Cytometry Use for Evaluating Lung Health in PLOS ONE Business Wire +17.39%
Sep-06-22 01:54PM	WallachBeth Capital Announces Closing Of bioAffinity Technologies, Inc. $7.8 Million Initial Public Offering PR Newswire -23.55%
11:28AM	bioAffinity Technologies, Inc. Announces Closing of $7.8 Million Initial Public Offering Business Wire
Sep-01-22 12:32PM	WallachBeth Capital Announce Pricing Of bioAffinity Technologies IPO At $6.125 Per Unit PR Newswire
08:15AM	Loading…
08:15AM	bioAffinity Technologies Announces Pricing of IPO Business Wire

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience